Recent research has shown that glucagon receptor agonism (in combination with glucagon-like peptide 1 receptor [GLP-1R] agonism) rather than antagonism is more promising as a therapeutic intervention of combating diabetes and other metabolic disorders (35, 36, 37, 38). Here, GCGR is linked to metabolic disease.